- This topic has 4 replies, 3 voices, and was last updated 9 years, 9 months ago by
.
-
IL28 is a gene.
Like most genes you get 1 from mum, and 1 from dad.
You can get either a “C” or a “T” IL28 gene from each of your parents.
In the days of interferon having “CC” ie 2 copies of the “C” IL28 gene improved your chances of SVR. Two copies of the “T” ie “TT” predicted you would probably fail. As you might expect “CT” or “TC” ie one “C” and one “T” from your parents put you in the middle.
With DAAs it’s not really important because TT, CT and CC people all do well. It’s probably still a little advantageous to have “CC” but there is little point in testing for this these days, and after all, there is nothing you can do about it.
I was wondering about this the other day when you posted the new Decision Support Tool.
i.e. For genotypes 2/4/5/6 is there any advantage when making a decision on treatment for the new Australian guidelines that recommend Peg/Riba with Sofosbuvir? Eg “if the patient has TT and maybe CT then follow EASL guidelines and prescribe Sof/Dac”
Or would using Sof with the Peg/Riba negate any advantage there?
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
Hmmm, on further reflection peg/riba is sub optimum for everyone regardless of their genes.
While it’s reasonably cost achievable to help our mums the best scenario is that PBS doesn’t end up discriminating against 9% of HCV infected people to save a few bucks.
Anyone know when the final rules get announced?
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
- You must be logged in to reply to this topic.